NCT05266248已完成1 期
Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Area under the concentration curve for plasma caffeine (AUC0-t)
研究概览
简要总结
Pilot study designed to characterize the plasma caffeine pharmacokinetic profile of encapsulated caffeine when consumed in the fasted and fed states.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male and female volunteers aged 18 to 55 years.
- •Have a BMI of 18 to 29.9 kg/m2 (inclusive)
- •Are regular caffeine consumers (average 1 to 3 caffeine-containing beverages per day, not to exceed 400 mg/ per day)
- •Willing to commit to 1 overnight stays (~36 hrs)
- •Able to comprehend and willing to sign an Informed Consent Form (ICF)
- •Willing to avoid caffeine-containing products for ≥48 hrs prior to dosing and until the completion of each test visit
- •Willing to avoid alcohol for ≥24 hrs prior to dosing
- •Willing to fast 10 hrs prior to dosing
- •Willing to stick to their usual dietary patterns and avoid grapefruit
- •Willing to stick to their usual physical activity level throughout the study
- •Willing to stick to their usual sleep pattern
- •Willing and able to consume a high-fat, high-caloric breakfast
- •No participation in any clinical trial within the past 30 days or 5 half lives and throughout this study, or any PEP protocol within the past 6 months.
排除标准
- •Reported history or clinical manifestations of significant metabolic (including type 1 or type 2 diabetes mellitus), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders unless deemed clinically not significant by investigator
- •Current or recent history (<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection
- •Current clinically significant viral infection
- •History of malignancy within the past 5 years, with the exception of cured basal cell or squamous cell carcinoma of the skin within 6 months
- •Are pregnant or breastfeeding or planning to become pregnant
- •Resting heart rate less than 45 bpm or greater than 100 bpm.
- •History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure 150/90 mm Hg)
- •History of significant surgery that may affect absorption of caffeine. Appendectomy and/or cholecystectomy will be allowed.
- •Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis).
- •Extreme dietary habits, including but not limited to intentional consumption of a high fiber diet, gluten-free, low-carb, vegan, ketogenic.
- •History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations.
- •More than one tobacco-containing or nicotine-containing product occasions per month on average, or use of such products within 48 hours prior to dosing of each study period
- •Use of any prescription or nonprescription drugs (including vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations) is prohibited within 7 days prior to the dose of study product, unless deemed acceptable by the Investigator.
- •Use of any medication known to have an interaction with caffeine including oral contraceptives (e.g., medications metabolized via the CYP1A2 pathway). Contraceptives with localized effects (e.g., copper and hormonal IUDs, vaginal ring) are acceptable, methods with systemic effects (e.g., patch or subdermal implants/devices) are not.
- •Use of any medication known to alter the pH of the gastrointestinal tract (e.g., proton-pump inhibitors, histamine H2-receptor antagonists (H2 blockers), antacids, etc.).
- •Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma within 2 weeks prior to Screening.
- •Receipt of blood products within 3 months prior to study entry.
- •Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
结局指标
主要结局
Area under the concentration curve for plasma caffeine (AUC0-t)
时间窗: Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion
Plasma caffeine pharmacokinetics
Peak caffeine concentration (Cmax)
时间窗: Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion
Plasma caffeine pharmacokinetics
Time to maximal plasma caffeine concentration (Tmax)
时间窗: Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion
Plasma caffeine pharmacokinetics
Plasma caffeine concentration by time profile
时间窗: Changes from pre-dose to 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours after the first sip of beverage ingestion
Plasma caffeine pharmacokinetics
次要结局
- Vital sign measurement: Systolic and diastolic blood pressure(Changes in systolic and diastolic blood pressure over 6.5 hours, from prior to blood sample collection at -30 minutes pre-dose to 2 and 6 hours after the first sip of beverage ingestion)
- Occurrence of Adverse events(From the first sip of beverage ingestion (Time 0) of the first dosing day, until the subject exits the study the evening of the second and last dosing day. The two dosing days are approximately 7 days apart.)
- Vital sign measurement: Heart rate(Changes in heart rate over 6.5 hours, from prior to blood sample collection at -30 minutes pre-dose to 2 and 6 hours after the first sip of beverage ingestion)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of CaffeineHealthy VolunteersNCT02109497Prana Biotechnology Limited18
已完成
1 期
Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage and Associated Mood and Physiological EffectsAlertnessNCT05096780PepsiCo Global R&D75
已完成
1 期
Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy VolunteersPlasma Caffeine ConcentrationNCT04281758PepsiCo Global R&D16
已完成
1 期
Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference PatchPainNCT03785613Grünenthal GmbH47
已完成
1 期
Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy SubjectsHealthy VolunteersNCT05368831NorthSea Therapeutics B.V.24